# Hydroxychloroquine, Azithromycin in the Treatment of Covid-19

> **NCT04405921** · PHASE3 · UNKNOWN · sponsor: **Centre Hôpital Universitaire Farhat Hached** · enrollment: 200 (estimated)

## Conditions studied

- SARS-CoV-2 Pneumonia
- COVID-19

## Interventions

- **DRUG:** Hydroxychloroquine 200 Mg Oral Tablet
- **DRUG:** Azithromycin 250 MG

## Key facts

- **NCT ID:** NCT04405921
- **Lead sponsor:** Centre Hôpital Universitaire Farhat Hached
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07
- **Primary completion:** 2020-12
- **Final completion:** 2021-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04405921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04405921, "Hydroxychloroquine, Azithromycin in the Treatment of Covid-19". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04405921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*